Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients

被引:0
|
作者
Kleiboeker, Hanna L. [1 ]
Wang, Jacob [2 ]
Borkowski, Nicole [3 ]
Miner, Brad [3 ]
Prom, Alyson [1 ]
Paplaczyk, Krista [1 ]
Wright, Jennifer [3 ]
Subramani, Mrinalini Venkata [4 ]
Arunachalam, Ambalavanan [4 ]
Betensley, Alan D. [4 ]
Tomic, Rade [4 ]
Myers, Catherine N. [4 ]
机构
[1] Northwestern Mem Hosp, Dept Pharm, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Northwestern Mem Hosp, Canning Thorac Inst, Dept Transplant Pulmonol, Div Pulm & Crit Care, Chicago, IL USA
[4] Northwestern Univ, Feinberg Sch Med, Dept Transplant Pulmonol, Div Pulm & Crit Care, Chicago, IL USA
关键词
solid organ transplant; lung transplant; cytomegalovirus; myelosuppression; REPLICATION;
D O I
10.1111/tid.14337
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Cytomegalovirus (CMV) is a driver of negative outcomes after lung transplant (LTX) and primary prophylaxis (PPX) with valganciclovir (VGC) is standard-of-care. VGC is associated with myelosuppression, prompting interest in letermovir (LTV). Methods: Adults receiving LTX between April 1, 2015, and July 30, 2022, at our institution were evaluated. Patients were excluded if low CMV risk (D-/R-), survived <90 days post-LTX, or transferred care before PPX withdrawal. Primary outcomes were leukopenia (white blood cell count [WBC] <= 3.0 x 10(9)/L), severe leukopenia (WBC <= 2.0 x 109/L), and neutropenia (absolute neutrophil count <= 1500 cells/<mu>L) requiring granulocyte-colony stimulating factor (GCSF) on PPX. Secondary outcomes included breakthrough CMV infection and post-PPX CMV infection. Results: 204 patients met inclusion criteria: 175 patients on VGC and 29 patients on LTV (after VGC conversion). Most patients received bilateral LTX (62.7%) with non-lymphocyte-depleting induction (96.6%) and moderate-risk serostatus (D+/R+, 48.5%). Patients transitioned from VGC to LTV after a mean of 178 days (SD 80.8 days) post-transplant. Patients on VGC experienced significantly more leukopenia (82.3% vs. 58.6%, p = 0.008), severe leukopenia (57.1% vs. 31.0%, p = 0.016), and neutropenia requiring GCSF (70.9% vs. 51.7%, p = 0.048). Breakthrough (5.7% vs. 3.4%, p = 0.955) and post-PPX (24.6% vs. 37.9%, p = 0.199) infections were similar. A subgroup analysis of patients with high-risk serostatus showed similar trends, though did not reach statistical significance. Conclusions: In this single-center study, the incidence of leukopenia and neutropenia requiring GCSF were reduced with LTV compared to VGC. Breakthrough and post-PPX infections were not significantly different. This evidence suggests that LTV has comparable efficacy with reduced myelosuppression compared to VGC in LTX recipients, and may be an appropriate alternative for PPX. image
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Use of Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant
    Kleiboeker, H.
    Wang, J.
    Borkowski, N.
    Miner, B.
    Mahesri, M.
    Subramani, M. Venkata
    Tomic, R.
    Arunachalam, A.
    Myers, C.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S72 - S72
  • [2] Use of Letermovir for Cytomegalovirus Prophylaxis in Pediatric Lung Transplant Patients
    Bhatt, N.
    Moulton, E. A.
    Melicoff-Portillo, E.
    Schrader, A.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S626 - S627
  • [3] Use of Letermovir for Cytomegalovirus (CMV) Prophylaxis in Orthotopic Heart Transplant Recipients
    Golob, S.
    Uriel, M.
    Batra, J.
    Gaine, M.
    Clerkin, K.
    Raikhelkar, J.
    Fried, J.
    Griffin, J.
    Restaino, S.
    Lee, S.
    Majure, D.
    Yuzefpolskaya, M.
    Colombo, P.
    Latif, F.
    Pereira, M.
    Choe, J.
    Jennings, D.
    Sayer, G.
    Uriel, N.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S330 - S330
  • [4] Assessment of Letermovir as Universal Prophylaxis for Cytomegalovirus Infection in Lung Transplant Recipients.
    Borges, L. F.
    Sparkman, T.
    Gutierrez, K.
    Banbury, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 988 - 988
  • [5] Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients
    Saltiel, Gregoire
    Faure, Emmanuel
    Assaf, Ady
    Chopin, Marie-Charlotte
    Moreau, Fanny
    Faure, Karine
    Goeminne, Celine
    Vuotto, Fanny
    [J]. CLINICAL TRANSPLANTATION, 2024, 38 (05)
  • [6] A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis
    Moore, W. Justin
    Boutin, Catherine-Audrey
    Tanna, Sajal
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2023, 36 (06) : 514 - 521
  • [7] Letermovir for cytomegalovirus prophylaxis in lung transplant recipients: A promising shift toward reduced myelotoxicity
    Alsharif, Muath
    Pennington, Kelly M.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (03)
  • [8] Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients
    Saullo, Jennifer L.
    Miller, Rachel A.
    [J]. ANNUAL REVIEW OF MEDICINE, 2023, 74 : 89 - 105
  • [9] Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis
    Abidi, Maheen Z.
    Molina, Kyle C.
    Garth, Krystle
    Gutman, Jonathan A.
    Weinberg, Adriana
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (05)
  • [10] Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients
    Golob, Stephanie
    Batra, Jaya
    DeFilippis, Ersilia M.
    Uriel, Matan
    Carey, Matt
    Gaine, Maureen
    Mabasa, Angelo
    Fried, Justin
    Raikelkar, Jayant
    Restaino, Susan
    Lee, Sun Hi
    Latif, Farhana
    Yuzefpolskaya, Melana
    Colombo, Paolo C.
    Choe, Jason
    Majure, David
    Jennings, Douglas
    Pereira, Marcus R.
    Clerkin, Kevin
    Sayer, Gabriel
    Uriel, Nir
    [J]. CLINICAL TRANSPLANTATION, 2022, 36 (12)